Literature DB >> 24691219

Role of acute graft-versus-host disease in the risk of bacteremia and invasive fungal disease after allogeneic hemopoietic stem cell transplantation in children. Results from a single-center observational study.

Elio Castagnola1, Francesca Bagnasco2, Roberto Bandettini3, Ilaria Caviglia4, Giuseppe Morreale5, Edoardo Lanino5, Stefano Giardino5, Cristina Moroni4, Riccardo Haupt2, Maura Faraci5.   

Abstract

Data on epidemiology of severe infectious complications, ie, bacteremia or invasive fungal disease (IFD), in children with acute graft-versus-host disease (aGVHD) after allogeneic hemopoietic stem cell transplantation (HSCT) are scarce. In a retrospective, single-center study, we analyzed the risk (hazard ratio [HR]) and the rate (episodes/1000 patients days at risk) of bacteremias and IFD in children receiving allogeneic HSCT, according to the type of donor (matched related [MRD] or alternative [AD]) and presence and grade of aGVHD. From 2000 to 2009, 198 children receiving 217 allogeneic HSCT developed 134 severe infectious episodes (103 bacteremias and 31 IFD). The type of donor (AD versus MRD) was the most important risk factor for the severe infections (P = .0052). In separate multivariable analysis for bacteremia and IFD, children receiving an AD HSCT had increased HR and rate of bacteremia compared with those receiving a MRD transplantation (P = .0171 and P = .0001, respectively), whereas the HR and the rate of IFD were significantly influenced by the grade of aGVHD (P = .0002 and P < .0001, respectively). Finally, infectious episodes occurred late after HSCT, especially in presence of severe aGVHD, and bacteremias were 3 to 6 times more frequent than IFD. These data may be important to design management strategies of infections in pediatric allogeneic HSCT.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute graft-versus-host disease; Allogeneic hemopoietic stem cell transplantation; Bacteremia; Children; Invasive fungal disease

Mesh:

Year:  2014        PMID: 24691219     DOI: 10.1016/j.bbmt.2014.03.026

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  4 in total

1.  Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study.

Authors:  Yoshitaka Inoue; Keiji Okinaka; Shigeo Fuji; Yoshihiro Inamoto; Naoyuki Uchida; Takashi Toya; Kazuhiro Ikegame; Tetsuya Eto; Yukiyasu Ozawa; Koji Iwato; Yoshinobu Kanda; Yoshiko Atsuta; Masao Ogata; Takahiro Fukuda
Journal:  Bone Marrow Transplant       Date:  2021-04-19       Impact factor: 5.483

Review 2.  Gut microbiota and hematopoietic stem cell transplantation: where do we stand?

Authors:  D Zama; E Biagi; R Masetti; P Gasperini; A Prete; M Candela; P Brigidi; A Pession
Journal:  Bone Marrow Transplant       Date:  2016-06-27       Impact factor: 5.483

3.  Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia-A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP.

Authors:  Herbert Pichler; Anita Lawitschka; Evgenia Glogova; Andre M Willasch; Irene von Luettichau; Thomas Lehrnbecher; Susanne Matthes-Martin; Peter Lang; Peter Bader; Karl W Sykora; Johanna Schrum; Bernhard Kremens; Karoline Ehlert; Michael H Albert; Michaela Kuhlen; Roland Meisel; Tayfun Guengoer; Brigitte Strahm; Bernd Gruhn; Ansgar Schulz; Wilhelm Woessmann; Ulrike Poetschger; Christina Peters
Journal:  Am J Hematol       Date:  2019-05-29       Impact factor: 10.047

4.  Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.

Authors:  Richard T Maziarz; Annie Guérin; Geneviève Gauthier; Julie Heroux; Maryia Zhdanava; Eric Q Wu; Simu K Thomas; Lei Chen
Journal:  Int J Hematol Oncol       Date:  2016-04-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.